newsfilter
← Latest News
ACCESS Newswire·

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

  • Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) Interim CEO Kraig Higginson will present at the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on Wednesday, October 8, 2025, at 1:00 p.m. Eastern.
  • Virtual 1x1 investor meetings are scheduled for Wednesday, October 8, 2025, 2 Thursday, October 9, 2025.
  • The presentation will cover updates on Aspire's patent-pending sublingual drug delivery technology 2 key 2025 2026 milestones.
  • Sublingual high-dose aspirin (lead program) targets an FDA request meeting for the 505(b)(2) pathway 2 New Drug Application (NDA) submission in H2 2025.
  • Sublingual ED medication aims to finalize formulation 2 manufacture test products in H1 2026, with Phase 1 pharmacokinetic clinical cross-over studies initiating mid-2026.
  • Sublingual semaglutide for diabetes 2 weight management targets finalization of formulation 2 test product manufacture in H1 2026, alongside an initial Phase 1 pharmacokinetic clinical cross-over study in H1 2026.
  • Aspire's technology delivers drugs directly to the bloodstream to avoid the gastrointestinal tract, potentially improving effectiveness 2 reducing side effects for small 2 large molecule therapeutics.
  • Registration for the conference is available at https://nobleconference.com/virtual-october/.